| Jun 19 |
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
|
| Jun 19 |
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
|
| Jun 19 |
The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not been profitable
|
| Jun 18 |
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
|
| Jun 17 |
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
|
| Jun 17 |
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
|
| Jun 14 |
Shattuck (STTK) Announces Positive Interim Data on Cancer Drug
|
| Jun 14 |
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
|
| Jun 14 |
What Makes Ligand (LGND) a New Strong Buy Stock
|
| Jun 6 |
Why Is Ligand (LGND) Up 4% Since Last Earnings Report?
|
